Median overall survival also almost doubled in the CDX-011-treated patients to a median 10 months versus 5.5 months for patients in the control arm.
Results were statistically significant although the benefit was derived from an analysis that included just 12 patients treated with CDX-011 and 4 patients treated with investigator's choice chemotherapy.
Based on these data, Celldex would like to run a confirmatory trial for CDX-011 in patients with triple-negative breast cancer that also contains high levels of GPNMB, pending FDA agreement. Approximately 5,000 to 9,000 breast cancer patients in the U.S. fit this category, according to various estimates.
CDX-011 may benefit a broader group of 30,000 to 40,000 breast cancer patients in the U.S. with tumors that contain high levels of GPNMB.Thirty-two percent of GPNMB high expressers responded to CDX-011 treatment compared to a 13% response rate in patients treated in the control arm in the phase II study. CDX-011 delayed the re-growth of tumors by a median 2.7 months compared to 1.5 months for the control arm. Median overall survival was 10 months for CDX-011 versus 5.7 months for the control arm. These results, culled from a subgroup of 38 patients, trended in favor of CDX-011 but were not statistically significant. CDX-011 does not appear to benefit breast cancer patients with tumors that contain minimal levels of the GPNMB protein. When all 122 patients in the phase II study were analyzed, treatment with CDX-011 resulted in a 16% response rate compared to a 14% response rate in patients treated with investigator's choice. The time to tumor re-growth and overall survival were essentially identical between both groups of patients. Celldex Chief Medical Officer Tom Davis said different cutoff levels of GPNMB expression were examined in the phase II study, with 25% and above determined to be the level at which CDX-011 showed the greatest efficacy. With relatively few patients to examine in the phase II study, however, the margin of error is greater. This raises the risk that the benefit of CDX-011 seen in the small phase II study may disappear when a larger study of the drug is conducted.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV